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as there will already be cross-resistance present. The
only barrier preventing the use of NFV for first-line
treatment is its prohibitive price.
The cost is exacerbated by the relatively high doses
needed in children. The standard dose recommended by
Roche is 20 - 30 mg/kg/dose 8-hourly.' However, recent
studies have suggested that this dosage results in
inadequate levels." Hayashi et al." found that a dosage
of 55 mg/kg/dose 12-hourly results in adequate levels. A
small study confirmed the efficacy of this 12-hourly
dosing in 11 subjects." Further studies, however, have
suggested that 12-hourly dosing may be problematic in
children, and a dose of 35 - 45 mg/kg/dose 8-hourly in
children over 2 years of age and 45 - 55 mg/kg/dose
every 8 hours in children under 2 years has therefore
been suggested (Professor Courtney Fletcher - personal
communication). Although there are as yet no good
data, preliminary pharmacokinetic studies suggest that
if the 12-hourly dose of NFV is preferred, a small dose of
ritonavir (Norvir; Abbott) (100 mg/m'/dose 12-hourly) be
added to boost the NFV levels (Fletcher - personal
communication).
Now that we have resolved the dosing issue, what about
the paediatric formulation? NFV comes in two dosage
forms, a 250 mg tablet and a powder for suspension. The
strength of the powder is 50 mg/1 gram scoop. This
means that every gram of powder contains only 50 mg
Nelfinavir (NFV) (Vira-cept; Roche) belongs to the class
of protease inhibitors. It is a very useful drug for a
number of reasons, although its high cost frequently
limits its use.
Since we were planning to discuss the individuol antiretrovirol agents in paediatrics, we thought that by starting
with NW we could set the record straight.
1. NFV is extremely well tolerated in children, its only
adverse effect of note being diarrhoea, which often
resolves spontaneously or responds to commercial
antidiarrhoeals. Only very seldom is it necessary to stop
the NFV."
In our Guidelines for Antiretroviral Treatment in Children published in the November edition of this journal,' 0
printer's gremlin crept in (see Erratum, p. 6, Southern African Journal ofHIV Medicine, February 2001). Thejist of
the error wos to make it oppear that there is no paediatric formulation for nelfinavir (NFV).
NELFINAVIR IN CHILDREN
Welcome to Kiddies Corner. We hope that this will become a regular feature in ourJournal. AtHIVconferences and
in the literature, paediatric HIV is sorely neglected. We hope that Kiddies Corner will be a forum where we can
discuss all ospects ofpaediotric HIVinfection. In this regard, we would like to draw your attention to our Internet-
based discussion graup, the Southern African HIV Clinicians Society Paediatric Discussion Group (pDG). This PDG
has been in operation since late last year and is popular for helping to resolve clinical problems and for exposing
paediatricions to the complexities ofontiretroviral therapy (ART) in children. Anyone who is not yet on the mailing
list and would like to join the PDG is welcome to send his or her e-mail addresstoleonlevin@54.co.za.
2. NFV has a unique resistance profile which makes it
ideal as a first-line agent The first mutation that
appears when resistance occurs is the D30N mutation."
This mutation does not confer resistance to any other PI.
If NFV continues to be used in this setting, secondary
mutations occur which do confer cross-resistance to
other Pis' Theoretically therefore (and also borne out by
a few studies),'" if there is failure of a NFV-containing
regimen due to resistance and a change is made early
on, there should be a good response to the other Pis or
to a dual PI regimen.
It is therefore evident that NFV is excellent as part of a
first-line regimen. If a child is started on another PI and
resistance develops, there is no point in changing to NFV
3. Although lipid abnormalities and lipodystrophy do
occur with NFV, there is some evidence that it is less
common with NFV than with the other Pis"'"
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In conclusion, NFV remains a useful protease inhibitor in
children. Its position is ideally 'first line', it is generally
well tolerated, and the tablets are the formulation of
choice. The 'package insert' dosage is too low, especially
in children aged under 2 years, and twice-daily dosing is
still unproven. The only real barrier to its more
widespread use is its price.
NFV, i.e. 95% of the product is inactive powder. Children
often have a great deal of difficulty in tolerating the
excess powder. As can be seen from Fig. 1, the crushed
tablets yield much less powder and are therefore much
better tolerated." The potential benefit of increasing
doses in smaller amounts is offset by the greater
adherence to treatment with the crushed tablets.
Because of the wide dosage range, it is usually possible
to tailor dosage to the nearest tablet or half tablet. The
crushed tablets can be administered with pudding, or
the whole tablets can be dissolved in water to produce
a dispersion that can be mixed with milk or chocolate
milk." As a result, most paediatric experts overseas are
no longer using the powder formulation but have opted
for the tablets instead.
Fig. 1. 80th containers contain 500 mg neJfinavir. The blue powder
on the left is from two crushed 250 mg tablets, while the white
powder on the right is 70 scoops of nelfinavi( powder for
suspension.
I am indebted to Professors Courtney Fletcher and Mark Kline
for the help they gave so freely in preparing this article, and
to Dr Cecil Levy for taking the photograph.
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